Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Health Mobile Apps Landscape in H2 2025
Trending in Health Mobile Apps: Current Trends, Rankings and Insights from H2…
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration…
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance…
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization Professional…
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed…
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader…
Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb collaboration
Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…